Ironwood Pharma Board Member Resigns for New Role
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Ironwood Pharma ( (IRWD) ) has provided an announcement.
On October 7, 2025, Andrew Dreyfus announced his resignation from the Board of Directors of Ironwood Pharmaceuticals, Inc., effective November 1, 2025. His departure is due to his new role as President and CEO of the National Institute for Health Care Management Foundation and is not related to any disagreements with Ironwood Pharmaceuticals. The company expressed gratitude for his contributions during his tenure.
The most recent analyst rating on (IRWD) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Ironwood Pharma stock, see the IRWD Stock Forecast page.
Spark’s Take on IRWD Stock
According to Spark, TipRanks’ AI Analyst, IRWD is a Neutral.
Ironwood Pharma’s stock score is primarily impacted by its financial instability, with significant debt and negative profitability. However, positive technical indicators provide some optimism, suggesting potential short-term momentum. The valuation remains unattractive due to negative earnings.
To see Spark’s full report on IRWD stock, click here.
More about Ironwood Pharma
Average Trading Volume: 1,366,453
Technical Sentiment Signal: Sell
Current Market Cap: $256.6M
See more insights into IRWD stock on TipRanks’ Stock Analysis page.
